Suzhou Geek Gene Technology

Suzhou Geek Gene Technology is an innovative biotechnology company specializing in the regulation of cell fate using high-throughput single-cell multi-omics and chemical reprogramming. The company has developed its proprietary AI-powered 'Cell Fate Navigation System' to engineer next-generation, long-lived T-cell therapies for advanced solid tumors. Its lead candidate, GK01, is an autologous tumor-reactive T-cell (TRT) therapy derived from tumor-infiltrating lymphocytes (TILs) that has entered Phase 1 clinical trials in China. By reversing T-cell exhaustion and enhancing ex vivo expansion, Geek Gene aims to overcome the key limitations of conventional cell therapies and provide highly effective, accessible treatments for cancer patients.